HUMA
Humacyte·NASDAQ
--
--(--)
--
--(--)
6.15 / 10
Outperform
Analyst consensus is overwhelmingly bullish with a 100% Strong Buy rating across three providers, yet historical win rates vary. Fund flows are robust (7.85/10), with positive small and extra-large inflows, but medium and large flows are negative. This divergence underscores the need for careful position sizing and risk management.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-21
InstitutionBenchmark
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for HUMA?
- HUMA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.15/10 (Outperform).
